Try our Advanced Search for more refined results
In re HIV Antitrust Litigation
Case Number:
3:19-cv-02573
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Baron & Budd
- Berry Silberberg
- Boies Schiller
- Crowell & Moring
- Dillingham & Murphy
- Duane Morris
- Faegre Drinker
- Glancy Prongay
- Goodwin Procter
- Hagens Berman
- Hangley Aronchick
- Hausfeld LLP
- Hilliard & Shadowen
- Holland & Knight
- Kanner & Whiteley
- Kellogg Hansen
- Kenny Nachwalter
- Kessler Topaz
- Kirkland & Ellis
- Law Offices of Francis O. Scarpulla
- Lockridge Grindal
- Milberg Coleman
- Miller Shah LLP
- Morrison Foerster
- NastLaw
- Nixon Peabody
- Nussbaum Law Group
- Pritzker Levine
- Proskauer Rose
- Radice Law Firm
- Rivero Mestre
- Robins Kaplan
- Spector Roseman
- Sperling & Slater
- Whatley Kallas
- White & Case
- Wilson Sonsini
- Zelle LLP
Companies
- Aetna Inc.
- Akros Pharma Inc.
- Albertsons Cos. Inc.
- Amneal Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- BlueCross BlueShield of South Carolina
- Bristol-Myers Squibb Co.
- Centene Corp.
- Cipla Ltd.
- CVS Health Corp.
- Florida Blue
- Fraternal Order of Police
- Gilead Sciences Inc.
- Health Care Service Corp.
- Humana Inc.
- Japan Tobacco
- Johnson & Johnson
- LifeWallet
- Mylan NV
- Rite Aid Corp.
- Service Employees International Union
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- Zydus Pharmaceuticals Inc.
Government Agencies
Sectors & Industries:
-
July 29, 2020
HIV Drug Suit Against Gilead, BMS And Janssen Trimmed
A California federal judge dismissed attempts to revive allegations of an antitrust conspiracy involving Gilead, Bristol-Myers Squibb and Janssen Pharmaceuticals to block generic competition and keep HIV medication prices artificially high in a decision unsealed Wednesday that nevertheless left intact key parts of the complaint.
-
July 16, 2020
Gilead Tries To Shake Antitrust Suit Over Expensive HIV Drugs
Gilead Sciences urged a California federal judge Thursday to nix AIDS activists and consumers' renewed allegations that it engaged in anti-competitive conduct with Bristol-Myers Squibb and Janssen Pharmaceuticals to block generic competition and keep HIV medication prices artificially high, arguing the plaintiffs have failed to properly identify a product market.
-
June 03, 2020
Gilead Can't Shake New HIV Antitrust Complaint, Court Told
Pharmaceutical giants accused of working together to block generic competition for blockbuster HIV treatments are using their latest motion to dismiss to rehash arguments the California federal court has already dealt with, the proposed class said Tuesday.
-
May 05, 2020
New HIV Antitrust Complaint, Same Problems, Gilead Says
Gilead Sciences, Bristol-Myers Squibb Co. and Janssen Pharmaceuticals urged a California federal judge Monday to toss newly rejiggered parts of an antitrust complaint alleging that they conspired to block competition for blockbuster HIV treatments, arguing that none of the failings that doomed part of the original complaint has been fixed.
-
March 04, 2020
Gilead Can't Duck Sweeping Competition Suit Over HIV Drugs
Gilead Sciences and several other drug companies remain mired in a sprawling lawsuit alleging they conspired to block competition for blockbuster HIV treatments, after a California federal judge issued a mixed ruling on their dismissal bids.
-
October 28, 2019
FTC Rips Gilead's 'Erroneous' Argument In HIV Drug Rumble
The Federal Trade Commission has waded into a lawsuit accusing Gilead Sciences Inc. of creating an HIV drug empire by using shadowy deals to block generic competition, assailing the company's argument that only one product market is relevant to the case.
-
September 04, 2019
Gilead Says HIV 'No Generic' Suit Is Baseless
Gilead Sciences Inc. urged a California federal court on Wednesday to toss a suit alleging it created an HIV drug empire using shadowy deals to block generic competition, arguing that its dealings were entirely aboveboard.
-
July 26, 2019
Meet The Top Attys In Gilead's 'No Generics' Antitrust Rumble
Lead lawyers are locked and loaded in an explosive antitrust case accusing Gilead Sciences of pocketing billions of dollars by monopolizing life-saving HIV medicines via a dark conspiracy with fellow drugmakers. Here, Law360 unpacks the allegations and introduces the hot-shot attorneys on both sides of the case.
-
June 25, 2019
Big Pharma's Biggest New Cases Of 2019: Midyear Report
Multibillion-dollar lawsuits targeting major drugmakers emerged with astonishing frequency during the first half of 2019, threatening civil and criminal liability for all manner of alleged wheeling and dealing. Here, Law360 highlights the latest developments and upcoming action in the pharmaceutical world's hottest new cases.
-
May 14, 2019
Gilead Built HIV Drug Empire On 'No Generic' Deals, Suit Says
Despite abysmal scientific innovation, Gilead Sciences Inc. constructed an HIV drug empire worth tens of billions of dollars by devising shadowy deals to block the use of lower-cost generics in combo medicines, according to a proposed class action filed Tuesday.
- ← Previous
- 1
- 2
- 3
- 4
- 5
- Next →